BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19. The event was fantastic. Our panelists included Elena Diez Cecilia, Director of Business Development and R&D Strategy at A2A...
BioIDEA and EVQLV are hosting a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19. Join us on Thursday, 5/14 at 4 PM EST for a panel discussion on the role of emerging technologies in the fight against COVID-19. If you'd...
Our CEO, Andrew Satz, has spent the last 15 years working remotely -- making him a veritable expert on the skill. He was recently a guest on the Gaper podcast where he shared three methods you can quickly implement to help you adjust to remote work. As this has become...
EVQLV is excited to announce we took first place in Columbia Engineering's Venture Competition (CVC). We've included a snippet from the announcement below. If you'd like to read the official release, you can do so here. In the Technology Challenge, avoMD and EVQLV...
The World Health Organization (WHO), yesterday, released a public statement for collaboration on COVID-19 treatment development of which Andrew Satz (CEO, EVQLV) gladly joined his name. Statement follows. We are scientists, physicians, funders and manufacturers who...
Our very own Brett Averso (CTO, EVQLV) was welcomed on the AI Podcast in 26.1 Minutes with hosts Brian Ray and Don Sheu. They discussed our work on COVID-19, the benefits of a computational approach to antibody research and drug discovery, our progress as a company...
Edward Turner of TMR Blog recently covered our work on COVID-19. He did a nice job summarizing the potential efficacy of our algorithm in an understandable and digestible manner, while including EVQLV's optimism on the project. See below. Andrew Satz is the CEO and...
Our work on COVID-19 antibodies was covered by insideBIGDATA. They did a fantastic job covering the piece originally published by Columbia Data Science Institute, highlighting a few choice gems. What our algorithms do is reduce the likelihood of drug-discovery failure...
Columbia Data Science Institute recently covered EVQLV's work towards developing therapeutic candidates against COVID-19 with antibodies. Two graduates of the Data Science Institute (DSI) at Columbia University are using computational design to quickly discover...